Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VHX-896 · 2 trials · 1 indication
As measured by plasma concentrations
as measured by plasma concentrations
As measured by the incidence of adverse events and clinically significant changes in laboratory values, ECG parameters, and vital signs
| Arm | Type | Description |
|---|---|---|
| Sequence A: fed then fasted | EXPERIMENTAL | - |
| Sequence B: fasted then fed | EXPERIMENTAL | - |
| Sequence A: VHX-896 then iloperidone | EXPERIMENTAL | - |
| Sequence B: Iloperidone then VHX-896 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| VHX-896 | DRUG | Oral tablet |
| VHX-896 and iloperidone | DRUG | oral tablet |
| Iloperidone and VHX-896 | DRUG | oral tablet |
Inclusion Criteria: * Healthy male and/or female participants between 18 to 55 years (inclusive). * Have a Body Mass Index (BMI) of \> 18.0 and \< 30.0 kg/m2; (BMI = weight (kg)/ \[height (m)\]2). * Good health as determined by no clinically significant deviations from normal in medical history, cl...
VHX-896 is an investigational small molecule being developed by Vanda Pharmaceuticals for use in schizophrenia and bipolar I disorder. It is currently in Phase 1 clinical development and has been studied in healthy volunteers as well as in patients with these conditions.
VHX-896 is a small molecule being studied as a potential treatment for schizophrenia and bipolar I disorder. The specific molecular target has not been disclosed in available clinical trial information.
VHX-896 is being developed by Vanda Pharmaceuticals Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol VNDA. The company is conducting Phase 1 clinical trials to evaluate the drug.
VHX-896 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Three Phase 1 trials have been completed, with a total enrollment of 49 participants.
VHX-896 has completed three Phase 1 trials: NCT04969211, a bioequivalence study in healthy volunteers; NCT06494397, a pharmacokinetic study in schizophrenia and bipolar I disorder; and NCT06803290, a food effect study in healthy volunteers. All trials were conducted in the United States.
VHX-896 is being studied in comparison to iloperidone tablets in bioequivalence and pharmacokinetic trials. The studies evaluate how VHX-896 compares to iloperidone, but VHX-896 is a distinct investigational drug being developed by Vanda Pharmaceuticals.